1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 34,200 | 35,200 | 12:58 | |
| 34,200 | 35,200 | 12:52 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.04. | Fortrea Holdings Inc: Fortrea Announces Date for First Quarter 2024 Financial Results and Conference Call | 2 | GlobeNewswire (USA) | ||
| 01.04. | Fortrea Holdings Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.03. | Research and Markets: 2024 Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report Featuring IQVIA, ICON, Parexel, Fortrea (formerly Labcorp), PPD/Thermo Fisher, and Syneos Health - ResearchAndMarkets.com | 484 | Business Wire | The "2024 Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report" has been added to ResearchAndMarkets.com's offering.
The biopharmaceutical clinical development landscape... ► Artikel lesen | |
| 22.03. | Where Fortrea Holdings Stands With Analysts | 2 | Benzinga.com | ||
| 13.03. | Fortrea Holdings Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 12.03. | Fortrea sells pair of businesses to private equity firm to become 'pure-play' CRO | 2 | FierceBiotech | ||
| 12.03. | Fortrea Holdings Inc: Fortrea unterzeichnet endgültige Vereinbarung zur Veräußerung der Geschäftsbereiche Endpoint Clinical und Patient Access an Arsenal Capital Partners | 302 | GlobeNewswire (Deutschland) | Vorgeschlagene Veräußerung der Geschäftsbereiche Endpoint Clinical und Fortrea Patient Access optimiert Fortreas strategische Ausrichtung als reines Auftragsforschungsinstitut
Schafft eigenständige... ► Artikel lesen | |
| 12.03. | Fortrea Holdings Inc. (FTRE) Q4 2023 Earnings Call Transcript | 1 | Insider Monkey | ||
| 11.03. | Fortrea Holdings GAAP EPS of -$0.41 misses by $0.54, revenue of $775.4M misses by $3.69M | 1 | Seeking Alpha | ||
| 11.03. | US STOCKS Hyatt, Fortrea, China ADRs | 1 | Reuters | ||
| 11.03. | Fortrea Holdings Inc reports results for the quarter ended in December - Earnings Summary | - | Reuters | ||
| 11.03. | Fortrea shares tumble after Q4 results despite revenue beat | 2 | Investing.com | ||
| 11.03. | Fortrea falls on downbeat forecast, Q4 loss | 1 | Reuters | ||
| 11.03. | Fortrea sells enabling services and patient access businesses for up to $345 million | 4 | Reuters | ||
| 11.03. | Fortrea Posts Loss In Q4; To Divest Endpoint Clinical And Patient Access Businesses | 1 | RTTNews | ||
| 11.03. | Fortrea signs agreement to divest certain assets to Arsenal Capital Partners | - | Reuters | ||
| 11.03. | Fortrea Holdings Inc: Fortrea Signs Definitive Agreement to Divest Endpoint Clinical and Patient Access Businesses to Arsenal Capital Partners | 237 | GlobeNewswire (Europe) | Proposed divestiture of Endpoint Clinical and Fortrea Patient Access businesses further streamlines Fortrea's strategic focus as a pure-play contract research organization
Creates standalone best-in-class... ► Artikel lesen | |
| 11.03. | Fortrea Holdings Inc: Fortrea Reports Fourth Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance | 170 | GlobeNewswire (Europe) | For the three months and full year ended December 31, 2023: Revenues of $775.4 million for the fourth quarter, $3,109.0 million for the full yearGAAP net loss of $(36.0) million for the fourth quarter... ► Artikel lesen | |
| 11.03. | Fortrea Holdings Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.03. | Deutsche Bank starts Fortrea stock with hold, sets $36 price target | 12 | Investing.com |
Seite:
1 2 3 Weiter >>
60 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,605 | +1,58 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,838 | +2,70 % | Ist es schon so weit? Raus aus KI, Biotech kaufen: Nvidia, Evotec, Defence Therapeutics und Bayer im Fokus | Wieder ein Schlag ins Kontor! Zum Monatsschluss April stürzt die Technologiebörse Nasdaq zum dritten Mal ab und zeigt mit 17.333 Punkten erneut große Schwäche. Nach einem langen Aufwärtstrend des NDX... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,842 | 0,00 % | Ginkgo Bioworks: Buy, Sell, or Hold? | ||
| BEAM THERAPEUTICS | 21,740 | 0,00 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,340 | 0,00 % | Recursion Pharmaceuticals: Recursion to Participate in Upcoming Investor Conferences | ||
| ONCOLYTICS BIOTECH | 1,050 | +1,94 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 27,900 | 0,00 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,914 | 0,00 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| SIGA TECHNOLOGIES | 9,320 | 0,00 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
| MERRIMACK PHARMACEUTICALS | 14,975 | 0,00 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
| VIR BIOTECHNOLOGY | 8,750 | 0,00 % | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
"Vir... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,990 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 9,330 | 0,00 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand | CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat... ► Artikel lesen | |
| BIO-PATH | 2,670 | 0,00 % | Looking Into Bio-Path Holdings' Recent Short Interest | ||
| BIOMEA FUSION | 11,570 | 0,00 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
FORTREA HOLDINGS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 35,000 Euro und damit +1,74 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
